Yada Kazuhiro, Kashima Kenji, Daa Tsutomu, Kitano Seigo, Fujiwara Sakuhei, Yokoyama Shigeo
Department of Pathology, Faculty of Medicine, Oita University, Oita 879-5593, Japan.
Am J Dermatopathol. 2004 Dec;26(6):463-71. doi: 10.1097/00000372-200412000-00004.
We investigated the expression of CD10 by an immunohistochemical method in 51 basal cell carcinomas (BCCs), eight pilomatricomas, five trichoblastomas, two trichofolliculomas, three sebaceomas, five sebaceous carcinomas, ten syringomas, two spiradenomas, ten poromas, four porocarcinomas, one eccrine duct carcinoma (not otherwise specified, NOS), six mixed tumors of apocrine origin, and nine squamous cell carcinomas (SCCs). We detected strong expression of CD10 in tumor cells of BCC (86%), and found that the smaller the number of positive tumor cells, the larger the number of positive stromal cells, in particular in sclerosing BCCs. Spearman's rank correlation test revealed a significant negative correlation in BCCs between the expression of CD10 in tumor cells and that in stromal cells (P = 0.001). In all pilomatricomas (100%) and in four trichoblastomas (80%), strong expression was also detected in tumor cells. There was no detectable expression in trichofolliculomas. One sebaceoma (33%) and two sebaceous carcinomas (40%) expressed CD10 in a similar fashion to BCCs. All tumors of eccrine gland origin, including syringoma, spiradenoma, poroma, porocarcinoma, and eccrine duct carcinoma (NOS), did not express CD10. Five mixed tumors (83%) were immunopositive. In SCC, CD10 was overexpressed only in the stromal cells. These findings support the hypothesis that BCC is derived from the folliculo-sebaceous apocrine unit, especially having the same origin as trichoblastoma and pilomatricoma. CD10 might be an indicator of tumor invasiveness if it is expressed in stromal cells, while it might be a marker of follicular differentiation if it is expressed in the actual tumor cells of cutaneous epithelial neoplasms.
我们采用免疫组织化学方法研究了51例基底细胞癌(BCC)、8例毛母质瘤、5例毛发上皮瘤、2例毛囊瘤、3例皮脂腺瘤、5例皮脂腺癌、10例汗腺腺瘤、2例螺旋腺瘤、10例汗孔瘤、4例汗孔癌、1例未另行规定的小汗腺导管癌(NOS)、6例大汗腺来源的混合瘤以及9例鳞状细胞癌(SCC)中CD10的表达情况。我们在BCC的肿瘤细胞中检测到CD10的强表达(86%),并且发现阳性肿瘤细胞数量越少,阳性基质细胞数量越多,尤其在硬化性BCC中。Spearman等级相关检验显示,BCC中肿瘤细胞和基质细胞中CD10的表达之间存在显著负相关(P = 0.001)。在所有毛母质瘤(100%)以及4例毛发上皮瘤(80%)的肿瘤细胞中也检测到强表达。毛囊瘤中未检测到表达。1例皮脂腺瘤(33%)和2例皮脂腺癌(40%)以与BCC相似的方式表达CD10。所有小汗腺来源的肿瘤,包括汗腺腺瘤、螺旋腺瘤、汗孔瘤、汗孔癌以及小汗腺导管癌(NOS),均不表达CD10。5例混合瘤(83%)免疫阳性。在SCC中,CD10仅在基质细胞中过表达。这些发现支持了BCC起源于毛囊皮脂腺大汗腺单位这一假说,尤其是与毛发上皮瘤和毛母质瘤具有相同起源。如果CD10在基质细胞中表达,它可能是肿瘤侵袭性的指标;而如果它在皮肤上皮性肿瘤的实际肿瘤细胞中表达,它可能是毛囊分化的标志物。